Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KLRSthis companyKalaris Therapeutics Inc	$2.40	-2.96×	1.63×	0×	-0.77×	212.6%	0.0%	0.0%	0.0%	-55.1%	-41.1%	-33.5%	0.02×	2.3×	-31.98×	12.23×	0.0%	0	-2.38	3	B
ARTVArtiva Biotherapeutics, Inc.	$4.22	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CNTBConnect Biopharma Holdings Limited	$0.76	-2.82×	3.74×	2,452.52×	-2.19×	-15.8%	100.0%	-90740.6%	-86687.5%	-132.2%	-135.7%	-32.9%	0.02×	0.69×	0×	3.74×	0.0%	2	-15.61	2	C+
CNTXContext Therapeutics Inc.	$0.20	-3.87×	2.31×	0×	-2.05×	231.0%	0.0%	0.0%	0.0%	-59.7%	-65.5%	-18.9%	0×	1.82×	0×	8.52×	0.0%	2	-5.58	3	B
IMAImageneBio Inc	$4.03	-0.72×	0.28×	46.85×	-0.28×	9.5%	-29.1%	-6056.4%	-5668.6%	-34.1%	-33.4%	-127.6%	0.08×	0.56×	0×	12.49×	0.0%	1	0.37	3	B
MGXMetagenomi, Inc. Common Stock	$0.73	-0.69×	0.38×	2.39×	-0.72×	-11909.0%	78.9%	-380.9%	-348.5%	-55.4%	-47.0%	-148.3%	0.26×	0.01×	0×	7.22×	0.0%	2	-3.67	2	C
Peer median	—	-1.25×	0.95×	2.39×	-1.1×	-15.8%	0.0%	-380.9%	-348.5%	-59.7%	-65.5%	-75.7%	0.08×	0.56×	0×	8.52×	0.0%	2	-3.67	2	—